OncoMatch/Clinical Trials/NCT06170710
Postoperative CCRT Followed by Immunotherapy in High-Risk LA HNSCC
Is NCT06170710 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies Anti-PD-1 monoclonal antibody for head and neck squamous cell carcinoma.
Treatment: Anti-PD-1 monoclonal antibody — This trial aims to evaluate whether the addition of anti-PD-1 antibody to adjuvant postoperative chemoradiotherapy could improve disease free survival in patients with high-risk locally advanced head and neck squamous cell carcinoma (HNSCC).
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Head and Neck Squamous Cell Carcinoma
Biomarker criteria
Required: PD-L1 (CD274) cps > 1 (cps > 1)
Performance status
ECOG 0–1(Restricted strenuous activity)
Demographics
Prior therapy
Cannot have received: anti-pd-1/pd-l1 therapy
Lab requirements
Blood counts
Adequate organ function
Kidney function
Adequate organ function
Liver function
Adequate organ function
Adequate organ function
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06170710 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior anti-pd-1/pd-l1 therapy disqualifies patients from enrollment.
Does this trial require CD274?
Yes, CD274 cps > 1 is a required biomarker for enrollment.
Is there an age limit?
Yes. Patients must be 70 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify